Physician profile
Lawrence Frank
NPI 1194743237
$896.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $315 · 2021: $139 · 2022: $228 · 2023: $44.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.07 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.07 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.43 | 2019-2021 | |
| Janssen Biotech, INC. | $217.43 | 2020-2022 | |
| Bard Peripheral Vascular, INC. | $99.05 | 2020 | |
| Abbvie INC. | $61.33 | 2020-2021 | |
| Vifor Pharma, INC. | $45.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $42.00 | 2022 | |
| Amgen INC. | $39.66 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.87 | 2020-2022 | |
| Ucb, INC. | $25.07 | 2023 | Briviact |
| Astellas Pharma US INC | $24.06 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2023 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $17.56 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.02 | 2021 | |
| Gilead Sciences, INC. | $16.90 | 2019 | |
| Akebia Therapeutics INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.